
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is on track to launch its revolutionary psilocybin-based treatment for treatment-resistant depression (TRD) in the first half of 2027 following the completion of its rolling NDA submission in the fourth quarter of 2026. The company has demonstrated strong clinical data for its TRD program with promising results from its Phase 3 trials, and is also pursuing research and development for potential treatments for other mental health disorders such as PTSD, with a current late-stage study underway. The company has a favorable label and expects a similar REMS to the existing one for Johnson & Johnson's SPRAVATO, positioning it well in the competitive landscape.
Bears say
Compass Pathways is in a niche market, and while its focus on developing therapies for mental health conditions is commendable, it may face challenges in gaining widespread market acceptance for its treatment. Despite having a proprietary formulation with Breakthrough Therapy designation and Innovative Licensing and Access Pathway designation, the company will likely face high development and marketing costs in order to succeed. Additionally, its limited track record and lack of revenue may make it a risky investment.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares